此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

神经内窥镜手术的功效和安全性大脑出血 (NESICH 2)

2026年11月11日 更新者:Rong Hu, MD、Southwest Hospital, China

神经内镜手术对大型脑内出血的功效和安全性:多中心,随机,受控的临床试验

This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.

研究概览

详细说明

Previous retrospective studies have demonstrated that neuroendoscopic surgery, compared to conventional craniotomy, significantly reduces operative duration and intraoperative blood loss, enhances hematoma evacuation rates, and improves postoperative outcomes, including neurological recovery, activities of daily living, and quality of life in patients with large cerebral hemorrhage. However, there is a paucity of prospective randomized controlled trials evaluating the efficacy of different surgical techniques for intracerebral hemorrhage. To address this gap, the investigators propose a multicenter, randomized, controlled clinical trial to compare the safety and efficacy of neuroendoscopic surgery versus craniotomy, aiming to provide evidence-based guidance for surgical decision-making in cerebral hemorrhage management.

研究类型

介入性

注册 (估计的)

384

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400038
        • 招聘中
        • Southwest Hospital
        • 接触:
    • Gansu
      • Wuwei、Gansu、中国、733000
        • 招聘中
        • Wuwei People's Hospital
        • 接触:
    • Guangxi
      • Wuzhou、Guangxi、中国、543001
        • 招聘中
        • Wuzhou Workers' Hospital
        • 接触:
    • Jilin
      • Siping、Jilin、中国、136000
        • 招聘中
        • Siping Central People's Hospital
        • 接触:
    • Sichuan
      • Dazhou、Sichuan、中国、635100
        • 招聘中
        • Dazhu County People's Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 18-80 years old, male or female;
  2. The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);
  3. Patients with supratentorial intracerebral hemorrhage who have obvious space-occupying effect caused by hematoma (midline structure shift > 6mm) or hematoma volume ≥ 45ml and require emergency surgery (including patients with signs of cerebral herniation such as decreased or dilated pupillary light reflex on one side);
  4. Before randomization, GCS score was 5-14, NIHSS score was ≥6;
  5. mRS Before onset: 0-1 score;
  6. Randomization within 24 hours after the first diagnostic CT;
  7. The patient or family members are informed and voluntarily sign the informed consent;

Exclusion Criteria:

  1. The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;
  2. Thalamic hemorrhage, primary ventricular hemorrhage;
  3. Platelet count <75×109/L, INR > 1.4;
  4. Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;
  5. Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;
  6. Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;
  7. Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;
  8. Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;
  9. Pregnant or breastfeeding women, or those who expect to become pregnant within one year;
  10. are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and/or epidemiological studies).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental Arm

Neuroendoscopic Surgery to remove intracranial hematoma

Subjects will receive Neuroendoscopic Surgery followed by standard medical management

有源比较器:Control Arm

Craniotomy to remove intracranial hematoma

Subjects will receive Craniotomy followed by standard medical management

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
大体时间:180 days

Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

180 days

次要结果测量

结果测量
措施说明
大体时间
Length of ICU
大体时间:Number of days from admission, up to 180 days

Duration of stay in the ICU

Number of days from admission, up to 180 days
Length of hospitalization
大体时间:Number of days from admission to discharge, up to 180 days

Duration of stay in the hospital

Number of days from admission to discharge, up to 180 days
mRS Shift Analysis of Neurological Improvement Between the Two Groups
大体时间:180 days

The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

180 days
mortality
大体时间:30 days, 90 days and 180 days

All cause mortality from onset to 180 days

30 days, 90 days and 180 days
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
大体时间:90 days and 180 days

The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.

90 days and 180 days
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
大体时间:30 days and 90 days

Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

30 days and 90 days
Operation duration
大体时间:From the beginning to the end of the surgery

The length of the operation

From the beginning to the end of the surgery
Peroperative bleeding
大体时间:During surgery

The amount of blood lost during surgery

During surgery
Intraoperative blood transfusion volume
大体时间:During surgery

Intraoperative blood transfusion volume

During surgery
Incidence of rebleeding and infection
大体时间:3 days, 7 days, and 30 days after randomization

Incidence of rebleeding and infection in the two groups within 3 days, 7 days, and 30 days after randomization

3 days, 7 days, and 30 days after randomization
Incidence of complications
大体时间:180 days

Incidence of other common complications within 180 days (epilepsy, hydrocephalus, pneumonia, gastrointestinal bleeding, deep vein thrombosis, cardiovascular and cerebrovascular events, etc.)

180 days
Incidence of adverse events and serious adverse events
大体时间:180 days

Incidence of adverse events and serious adverse events in the two groups within 180 days

180 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Rong Hu, MD、PLA Army Medical University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年6月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2025年3月18日

首先提交符合 QC 标准的

2025年3月18日

首次发布 (实际的)

2025年3月25日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅